Mass Spectrometry | CHOP Research Institute
 

Mass Spectrometry

The Small Molecule and Metabolite Core is focused on assay development, validation, and sample analysis utilizing the latest mass spectrometry techniques.

Published on
Apr 27, 2022
Dr. Nissim studies the relationship of the metabolome and the fluxome to the genome in normal and disease states.

The Nissim Lab is led by a biochemist and a pioneer in the application of stable isotopes, mass spectrometry, and Nuclear Magnetic Resonance to study metabolome and fluxome and their coupling to genome in normal and disease states.

Translational genomics in childhood cancers is the central focus of the Diskin Lab, which works to identify the inherited and acquired genetic drivers of cancer by combining quantitative computational methods with rigorous experimental approaches in the lab.

Dr. Master works to understand the biochemical pathways related to inborn errors of metabolism, particularly as they relate to mitochondrial function. He also focuses on bioinformatics and machine learning solutions to problems in mass spectrometry and laboratory medicine.

E-mail:
masters [at] chop.edu
Published on
Jun 8, 2020
The Penn Vet Working Dog Center teams up with Audrey Odom John, MD, PhD, to work toward developing a ‘breathalyzer’ test for COVID-19.

Dr. Cardinale's research is focused on understanding the mechanisms of gene expression and gene regulation in autoimmune diseases, including inflammatory bowel disease, type 1 diabetes, and systemic sclerosis. He uses data from large-scale genomic studies to identify disease-causing genetic variants and functionally explore the target genes of those variants.

E-mail:
cardinalec [at] chop.edu

Dr. Nissim is a biochemist and a pioneer in the application of stable isotopes, mass spectrometry, and nuclear magnetic resonance to study metabolome and fluxome and their coupling to genome in normal and disease states. His long-standing interest focuses on understanding the cause, mechanisms, and outcome of metabolic disorders.

E-mail:
nissim [at] chop.edu

Dr. Diskin's research is focused on translational genomics in childhood cancers. Her laboratory seeks to identify the genetic basis of childhood cancers by combining quantitative computational methods with rigorous "wet-lab" experimental approaches. In parallel, she has developed, and is applying, a proteogenomic approach to identify novel immunotherapeutic targets for high-risk and relapsed pediatric malignancies.

E-mail:
diskin [at] chop.edu
Published on
Jul 1, 2014
A new approach being developed at The Children’s Hospital of Philadelphia and the University of Pennsylvania could allow investigators to know within days if a chosen therapy reverses the intracellular mechanisms that go awry in Friedreich’s Ataxia (FA), a genetic mitochondrial disease